Dr Abhishek is a Clinical Associate Professor of Rheumatology at the University of Nottingham and Honorary Consultant Rheumatologist at the Nottingham University Hospitals NHS Trust since September 2014. Prior to that he was a Consultant Rheumatologist at the Cambridge University Hospitals NHS Foundation Trust for one and a half years.
He completed higher specialist training in February 2013, gaining dual Certification in General Internal Medicine and Rheumatology from East Midlands Healthcare Workforce Deanery. His higher specialist training was interspersed with a PhD at Nottingham University and post-doctoral experience at The University of Birmingham.
He has diverse research interests including epidemiology of rheumatic diseases, clinical studies in crystal arthritis, osteoarthritis and fibromyalgia. Over the last 4 years he has had research funding as a principal investigator to the tune of £2.2 million from Arthritis Research UK, National Institute of Health Research, Rosetrees Charitable Trust, AstraZeneca, Oxford Immunotech, Nottingham University Hospitals NHS Trust Charity, and the European League Against Rheumatism. He was previously the lead for musculoskeletal diseases and disability (MDD) module for undergraduate medical education at the University of Nottingham.
He is also the Founding co-convenor of British Society for Rheumatology Crystal Arthritis Special Interest Group, Associate Editor BMC Rheumatology, and on the editorial board of Rheumatology (Oxford), Joint Bone Spine. He is part of the European League Against Rheumatism Undergraduate School of Rheumatology and have given invited lectures at the British Society for Rheumatology, Gout crystal and hyperuricemia network (G-CAN), and European League Against Rheumatism annual meetings on several occasions.
He supervises or co-supervises 8 PhD students in Academic Rheumatology.
- What is the clinical and cost-effectiveness of using a goal-directed allopurinol-based treat-to-target protocol in people with recurrent gout attacks? (NIHR-HTA)
- Beta blocker use, osteoarthritis pain and total joint replacement in the general population: a prospective cohort study using data from the Clinical Practice Research Datalink (NIHR-RfPB)
- Does increased expression of inflammatory genes influence gout onset and severity (Rosetrees Trust)
- Omega-3 fatty acids for the prophylaxis of acute attacks of gout on initiating urate lowering treatment - feasibility study for a randomised controlled trial (ARUK)
- Principal investigator for Developing a complex package of care for knee pain - package development and feasibility RCT, Research Area 5 [ Nottingham NIHR Biomedical Research Centre, Musculoskeletal Theme (NIHR, £3,677,177, Awarded November 2016), 36 months]
- Harnessing the potential of 17-HDHA a novel biomarker of OA pain status (Arthritis Research UK)
ABHISHEK A and DOHERTY M, 2015. Understanding placebo effects in rheumatology. Joint, bone, spine. 82(4), 222-4 ABHISHEK, A, DOHERTY, S, MACIEWICZ, R, MUIR, K, ZHANG, W and DOHERTY, M, 2014. Association between low cortical bone mineral density, soft-tissue calcification, vascular calcification and chondrocalcinosis: a case-control study. Annals of the Rheumatic Diseases: Ann Rheum Dis. 73, 1997-2002
ABHISHEK A, 2014. Calcium pyrophosphate deposition. British journal of hospital medicine (London, England : 2005). 75(4), C61-4